{
    "2021-09-22": [
        [
            {
                "time": "",
                "original_text": "天坛生物：公司国内市场的主要销售模式是将产品通过配送商销往各级医疗机构和零售药店等终端客户",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "销售模式",
                        "配送商",
                        "医疗机构",
                        "零售药店"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "",
                "original_text": "天坛生物：目前永安血制项目尚未正式投产",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "永安血制",
                        "未投产"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "天坛生物：“静注COVID-19人免疫球蛋白（pH4）”尚需完成临床试验等，预计短期内无法形成销售收入",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "静注COVID-19人免疫球蛋白",
                        "临床试验",
                        "短期",
                        "无收入"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "天坛生物：公司所属成都蓉生药业有限责任公司已获得“人凝血因子Ⅷ”的药品注册证书，并已通过GMP符合性检查，可进行该产品的生产、上市和销售",
                "features": {
                    "keywords": [
                        "天坛生物",
                        "成都蓉生",
                        "人凝血因子Ⅷ",
                        "药品注册证书",
                        "GMP符合性检查",
                        "生产",
                        "上市",
                        "销售"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}